Literature DB >> 7479344

Differential modulation of alpha 2-adrenergic and mu-opioid spinal antinociception by neuropeptide FF.

V K Kontinen1, E A Kalso.   

Abstract

Neuropeptide FF (NPFF) has been found to act as an antiopioid peptide. However, IT NPFF has recently been shown to potentiate the antinociceptive effects of IT morphine and to produce antinociception on its own. The aim of this study was to find out whether pretreatment with NPFF causes a comparable potentiation of dexmedetomidine-induced antinociception. NPFF (0.05-10.0 nmol) produced no antinociceptive effects in the rat tail flick test. NPFF potentiated the antinociceptive effect of IT morphine (7.8 nmol). This potentiation was prevented by IT naltrindole (28 nmol), which did not attenuate the antinociceptive effect of morphine. Dexmedetomidine (1.6-6.4 nmol) produced a dose-dependent antinociceptive effect, which was not potentiated by NPFF. Activation of the endogenous delta-opioid system due to the antiopioid effect of IT NPFF is proposed as an explanation to the reported differential action of NPFF on the mu-opioid and the alpha 2-adrenergic systems.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7479344     DOI: 10.1016/0196-9781(95)00068-u

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  6 in total

1.  Spinal effect of a neuropeptide FF analogue on hyperalgesia and morphine-induced analgesia in mononeuropathic and diabetic rats.

Authors:  C Courteix; M A Coudoré-Civiale; A M Privat; J M Zajac; A Eschalier; J Fialip
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  Nonpeptide small molecule agonist and antagonist original leads for neuropeptide FF1 and FF2 receptors.

Authors:  V Blair Journigan; Christophe Mésangeau; Neha Vyas; Shainnel O Eans; Stephen J Cutler; Jay P McLaughlin; Catherine Mollereau; Christopher R McCurdy
Journal:  J Med Chem       Date:  2014-10-21       Impact factor: 7.446

3.  The multifunctional peptide DN-9 produced peripherally acting antinociception in inflammatory and neuropathic pain via μ- and κ-opioid receptors.

Authors:  Biao Xu; Mengna Zhang; Xuerui Shi; Run Zhang; Dan Chen; Yong Chen; Zilong Wang; Yu Qiu; Ting Zhang; Kangtai Xu; Xiaoyu Zhang; Wolfgang Liedtke; Rui Wang; Quan Fang
Journal:  Br J Pharmacol       Date:  2019-12-23       Impact factor: 8.739

4.  BN-9, a chimeric peptide with mixed opioid and neuropeptide FF receptor agonistic properties, produces nontolerance-forming antinociception in mice.

Authors:  Ning Li; Zheng-Lan Han; Zi-Long Wang; Yan-Hong Xing; Yu-Long Sun; Xu-Hui Li; Jing-Jing Song; Ting Zhang; Run Zhang; Meng-Na Zhang; Biao Xu; Quan Fang; Rui Wang
Journal:  Br J Pharmacol       Date:  2016-04-21       Impact factor: 8.739

5.  Intracerebroventricular Neuropeptide FF Diminishes the Number of Apneas and Cardiovascular Effects Produced by Opioid Receptors' Activation.

Authors:  Piotr Wojciechowski; Kryspin Andrzejewski; Katarzyna Kaczyńska
Journal:  Int J Mol Sci       Date:  2020-11-25       Impact factor: 5.923

6.  Opposite effects of neuropeptide FF on central antinociception induced by endomorphin-1 and endomorphin-2 in mice.

Authors:  Zi-long Wang; Quan Fang; Zheng-lan Han; Jia-xin Pan; Xu-hui Li; Ning Li; Hong-hai Tang; Pei Wang; Ting Zheng; Xue-mei Chang; Rui Wang
Journal:  PLoS One       Date:  2014-08-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.